HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target.
June 27, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab and maintained a $50 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $50 price target by a reputable analyst suggests a positive outlook for Genmab. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100